Kyntra Bio Inc (KYNB) Stock Price, Quote & News

Company Profile

Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 978 1200

Fax: 415 978 1902

Website: www.kyntrabio.com

Address:

350 Bay Street, Suite 100 #6009, San Francisco, United States

MaxMiamiFl Jun. 4 at 3:35 PM

$KYNB LETS GO!!!!!! $20++++++

1 · Reply

ARKADIY_PAROVOZOV Jun. 4 at 9:47 AM

$KYNB Roxadustat Impurity 175 added to PubChem database — technical update for research and quality control purposes. https://pubchem.ncbi.nlm.nih.gov/compound/Roxadustat-Impurity-175

0 · Reply

ARKADIY_PAROVOZOV Jun. 4 at 9:47 AM

$KYNB Anemia drugs market report highlights HIF-PH inhibitors like Roxadustat as a growing segment in CKD treatment. https://www.linkedin.com/pulse/anemia-drugs-market-insights-future-revenue-potential-bysrc/

0 · Reply

ARKADIY_PAROVOZOV Jun. 4 at 9:47 AM

$KYNB New preclinical study suggests Roxadustat may help protect against thoracic aortic dissection by activating HIF-1α-mediated mitophagy and inhibiting ferroptosis. Interesting potential beyond anemia. https://www.researchgate.net/publication/405343485_Roxadustat_Ameliorates_Thoracic_Aortic_Dissection_by_Activating_HIF-1a-Mediated_Mitophagy_to_Inhibit_Ferroptosis

0 · Reply

ARKADIY_PAROVOZOV Jun. 4 at 9:18 AM

$KYNB a strange premarket on stocktwits. Investing and yahoo are different from stocktwits.

0 · Reply

ARKADIY_PAROVOZOV Jun. 3 at 9:31 AM

$KYNB ROXSTAR registry (China) showed long-term safety and good efficacy of roxadustat in CKD anemia patients, with 83-86% achieving target hemoglobin over 52 weeks. Supportive real-world data, but from Chinese population. https://www.researchgate.net/publication/392197177_Long-term_safety_and_effectiveness_of_roxadustat_in_Chinese_patients_with_chronic_kidney_disease-associated_anemia_The_ROXSTAR_registry

1 · Reply

MaxMiamiFl Jun. 2 at 3:53 PM

$KYNB Any updates about the compliance topic??

1 · Reply

MaxMiamiFl Jun. 2 at 2:59 PM

$KYNB The imaging product can be a big winner. ....IF

0 · Reply

ARKADIY_PAROVOZOV Jun. 2 at 1:21 PM

$KYNB FG-3180 (CD46-targeted ImmunoPET) showed promising First-in-Human data at SNMMI 2026. It detected 144 bone lesions vs 99 by standard bone scan (+45%) and 33 soft tissue sites vs 14 by CT (+136%). Higher uptake also trended with better PSA50 response to FG-3246. Early but encouraging results for the companion biomarker.

0 · Reply

mjtwins16 Jun. 2 at 9:12 AM

$KYNB https://www.urotoday.com/conference-highlights/snmmi-2026/169541-snmmi-2026-first-in-human-cd46-targeted-immunopet-imaging-with-89zr-dfo-ys5-in-mcrpc.html

0 · Reply

Kyntra Bio Earnings Call Transcript: Q1 2026

May 11, 2026, 5:00 PM EDT - 24 days ago

Kyntra Bio Earnings release: Q1 2026

May 11, 2026, 5:00 PM EDT - 24 days ago

Kyntra Bio Slides: Q1 2026

May 11, 2026, 5:00 PM EDT - 24 days ago

Kyntra Bio Quarterly report: Q1 2026

May 11, 2026, 4:05 PM EDT - 24 days ago

Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update

May 4, 2026, 4:05 PM EDT - 4 weeks ago

Kyntra Bio to Report First Quarter 2026 Financial Results

Apr 27, 2026, 8:00 AM EDT - 5 weeks ago

Kyntra Bio Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 5 weeks ago

Kyntra Bio Proxy statement: Proxy filing

Apr 13, 2026, 1:30 PM EDT - 7 weeks ago

Kyntra Bio Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 8, 2026, 4:05 PM EDT - 2 months ago

Kyntra Bio to Present at the 25th Annual Needham Virtual Healthcare Conference

Mar 16, 2026, 5:00 PM EDT - 2 months ago

Kyntra Bio Earnings Call Transcript: Q4 2025

Mar 16, 2026, 5:00 PM EDT - 2 months ago

Kyntra Bio Annual report: Q4 2025

Mar 16, 2026, 5:00 PM EDT - 2 months ago

Kyntra Bio Earnings release: Q4 2025

Mar 16, 2026, 5:00 PM EDT - 2 months ago

Kyntra Bio Slides: Q4 2025

Mar 16, 2026, 4:02 PM EDT - 2 months ago

Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 11, 2026, 2:20 PM EDT - 3 months ago

Kyntra Bio Transcript: Leerink Global Healthcare Conference 2026

Mar 11, 2026, 7:00 AM EDT - 3 months ago

Kyntra Bio Slides: Corporate presentation

Mar 9, 2026, 7:00 AM EDT - 3 months ago

Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results

Feb 26, 2026, 2:40 PM EST - 3 months ago

Kyntra Bio Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

2026-02-23T22:16:08.000Z - 3 months ago

Kyntra Bio announces positive data from Phase 1b/2 study of FG-3246

Feb 23, 2026, 5:10 PM EST - 3 months ago

Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026

Feb 17, 2026, 4:05 PM EST - 3 months ago

Kyntra Bio to Participate in Upcoming Investor Conferences

Jan 7, 2026, 7:30 AM EST - 5 months ago

FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum

Nov 10, 2025, 5:00 PM EST - 7 months ago

Kyntra Bio Earnings Call Transcript: Q3 2025

Nov 10, 2025, 5:00 PM EST - 7 months ago

Kyntra Bio Quarterly report: Q3 2025

Nov 10, 2025, 5:00 PM EST - 7 months ago

Kyntra Bio Earnings release: Q3 2025

Nov 10, 2025, 5:00 PM EST - 7 months ago

Kyntra Bio Slides: Q3 2025

Nov 3, 2025, 4:02 PM EST - 7 months ago

FibroGen to Report Third Quarter 2025 Financial Results

Sep 24, 2025, 7:00 AM EDT - 9 months ago

FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer

Sep 9, 2025, 12:00 PM EDT - 9 months ago

Kyntra Bio Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Aug 27, 2025, 4:02 PM EDT - 10 months ago

FibroGen to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 18, 2025, 7:00 AM EDT - 10 months ago

FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation

Aug 11, 2025, 5:00 PM EDT - 10 months ago

Kyntra Bio Earnings Call Transcript: Q2 2025

Aug 11, 2025, 5:00 PM EDT - 10 months ago

Kyntra Bio Quarterly report: Q2 2025

Aug 11, 2025, 5:00 PM EDT - 10 months ago

Kyntra Bio Earnings release: Q2 2025

Aug 11, 2025, 5:00 PM EDT - 10 months ago

Kyntra Bio Slides: Q2 2025

Aug 11, 2025, 4:02 PM EDT - 10 months ago

FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 4, 2025, 4:02 PM EDT - 10 months ago

FibroGen to Report Second Quarter 2025 Financial Results

Jun 12, 2025, 4:02 PM EDT - 1 year ago

FibroGen Announces 1-for-25 Reverse Stock Split

Jun 9, 2025, 4:02 PM EDT - 1 year ago

FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors

May 12, 2025, 5:00 PM EDT - 1 year ago

Kyntra Bio Earnings Call Transcript: Q1 2025

May 12, 2025, 5:00 PM EDT - 1 year ago

Kyntra Bio Quarterly report: Q1 2025

May 12, 2025, 5:00 PM EDT - 1 year ago

Kyntra Bio Earnings release: Q1 2025

May 12, 2025, 5:00 PM EDT - 1 year ago

Kyntra Bio Slides: Q1 2025

May 12, 2025, 4:02 PM EDT - 1 year ago

FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 4:24 AM EDT - 1 year ago

Duchenne Muscular Dystrophy (DMD) Pipeline Insight Report 2025, Featuring Analysis of Vamorolone (Santhera), Givinostat (Italfarmaco), and Pamrevlumab (Fibrogen)

May 5, 2025, 4:05 PM EDT - 1 year ago

FibroGen to Report First Quarter 2025 Financial Results

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Kyntra Bio Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Kyntra Bio Proxy statement: Proxy Filing

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Kyntra Bio Proxy statement: Proxy Filing

Apr 2, 2025, 4:05 PM EDT - 1 year ago

FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 17, 2025, 5:00 PM EDT - 1 year ago

Kyntra Bio Earnings Call Transcript: Q4 2024

Mar 17, 2025, 5:00 PM EDT - 1 year ago

Kyntra Bio Annual report: Q4 2024

Mar 17, 2025, 5:00 PM EDT - 1 year ago

Kyntra Bio Earnings release: Q4 2024

Mar 17, 2025, 5:00 PM EDT - 1 year ago

Kyntra Bio Slides: Q4 2024

Mar 17, 2025, 4:05 PM EDT - 1 year ago

FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 4:45 PM EST - 1 year ago

FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results

Feb 20, 2025, 8:30 AM EST - 1 year ago

Kyntra Bio Transcript: Status Update

Feb 20, 2025, 8:30 AM EST - 1 year ago

Kyntra Bio Press release: Status Update

Feb 20, 2025, 8:30 AM EST - 1 year ago

Kyntra Bio Slides: Status Update

Feb 20, 2025, 6:40 AM EST - 1 year ago

FibroGen sells China unit to AstraZeneca in deal worth $160 million

AZN

Feb 20, 2025, 6:30 AM EST - 1 year ago

FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million

Dec 16, 2024, 8:05 AM EST - 1 year ago

FibroGen Appoints David DeLucia as Chief Financial Officer

Nov 12, 2024, 5:00 PM EST - 1 year ago

Kyntra Bio Earnings Call Transcript: Q3 2024

Nov 12, 2024, 5:00 PM EST - 1 year ago

Kyntra Bio Quarterly report: Q3 2024

Nov 12, 2024, 5:00 PM EST - 1 year ago

Kyntra Bio Earnings release: Q3 2024

Nov 12, 2024, 5:00 PM EST - 1 year ago

Kyntra Bio Slides: Q3 2024

Nov 12, 2024, 4:05 PM EST - 1 year ago

FibroGen Reports Third Quarter 2024 Financial Results

Nov 4, 2024, 4:05 PM EST - 1 year ago

FibroGen to Report Third Quarter 2024 Financial Results

Sep 10, 2024, 3:00 PM EDT - 1 year ago

Kyntra Bio Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Aug 6, 2024, 5:00 PM EDT - 1 year ago

Kyntra Bio Earnings Call Transcript: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 1 year ago

Kyntra Bio Quarterly report: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 1 year ago

Kyntra Bio Earnings release: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 1 year ago

Kyntra Bio Slides: Q2 2024

Jul 30, 2024, 4:07 PM EDT - 2 years ago

FibroGen to Report Second Quarter 2024 Financial Results

Jun 28, 2024, 8:00 AM EDT - 2 years ago

Kyntra Bio Registration statement: Registration Filing

Jun 10, 2024, 10:00 AM EDT - 2 years ago

Kyntra Bio Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 3, 2024, 4:05 PM EDT - 2 years ago

FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen's Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials

Jun 3, 2024, 4:02 PM EDT - 2 years ago

FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors

May 23, 2024, 5:05 PM EDT - 2 years ago

FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology

May 20, 2024, 1:30 PM EDT - 2 years ago

Kyntra Bio Transcript: H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 7, 2024, 7:00 AM EDT - 2 years ago

FibroGen to Participate in Upcoming Investor Conferences

May 6, 2024, 5:00 PM EDT - 2 years ago

Kyntra Bio Earnings Call Transcript: Q1 2024

May 6, 2024, 5:00 PM EDT - 2 years ago

Kyntra Bio Quarterly report: Q1 2024

May 6, 2024, 5:00 PM EDT - 2 years ago

Kyntra Bio Earnings release: Q1 2024

May 6, 2024, 5:00 PM EDT - 2 years ago

Kyntra Bio Slides: Q1 2024

May 6, 2024, 4:02 PM EDT - 2 years ago

FibroGen Reports First Quarter 2024 Financial Results

Apr 29, 2024, 7:00 AM EDT - 2 years ago

FibroGen to Report First Quarter 2024 Financial Results

Apr 24, 2024, 4:02 PM EDT - 2 years ago

FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology A

Apr 24, 2024, 8:00 AM EDT - 2 years ago

Kyntra Bio Proxy statement: Proxy Filing

Apr 24, 2024, 8:00 AM EDT - 2 years ago

Kyntra Bio Proxy statement: Proxy Filing

Apr 9, 2024, 3:00 PM EDT - 2 years ago

Kyntra Bio Transcript: 23rd Annual Needham Virtual Healthcare Conference

Apr 9, 2024, 3:00 PM EDT - 2 years ago

Kyntra Bio Slides: 23rd Annual Needham Virtual Healthcare Conference

Apr 2, 2024, 5:46 PM EDT - 2 years ago

FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer

Mar 26, 2024, 7:00 AM EDT - 2 years ago

FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference

Mar 11, 2024, 7:00 AM EDT - 2 years ago

FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer

Feb 26, 2024, 5:00 PM EST - 2 years ago

Kyntra Bio Earnings Call Transcript: Q4 2023

Feb 26, 2024, 5:00 PM EST - 2 years ago

Kyntra Bio Annual report: Q4 2023

Feb 26, 2024, 5:00 PM EST - 2 years ago

Kyntra Bio Earnings release: Q4 2023

Feb 26, 2024, 5:00 PM EST - 2 years ago

Kyntra Bio Slides: Q4 2023

Feb 26, 2024, 4:18 PM EST - 2 years ago

FibroGen regains rights to anemia drug from AstraZeneca

AZN

Feb 26, 2024, 4:06 PM EST - 2 years ago

FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 26, 2024, 4:05 PM EST - 2 years ago

FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea

Feb 20, 2024, 7:00 AM EST - 2 years ago

FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results

Feb 13, 2024, 10:30 AM EST - 2 years ago

Kyntra Bio Transcript: Study Update

Feb 5, 2024, 7:00 AM EST - 2 years ago

FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024

Jan 25, 2024, 7:00 AM EST - 2 years ago

FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network's Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer

Jan 10, 2024, 3:00 PM EST - 2 years ago

Kyntra Bio Slides: Corporate Presentation

Dec 9, 2023, 5:02 PM EST - 2 years ago

FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting

Nov 6, 2023, 5:00 PM EST - 2 years ago

Kyntra Bio Earnings Call Transcript: Q3 2023

Nov 6, 2023, 5:00 PM EST - 2 years ago

Kyntra Bio Quarterly report: Q3 2023

Nov 6, 2023, 5:00 PM EST - 2 years ago

Kyntra Bio Earnings release: Q3 2023

Nov 6, 2023, 5:00 PM EST - 2 years ago

Kyntra Bio Slides: Q3 2023

Nov 6, 2023, 4:01 PM EST - 2 years ago

FibroGen Reports Third Quarter 2023 Financial Results

Oct 23, 2023, 7:00 AM EDT - 2 years ago

FibroGen to Report Third Quarter 2023 Financial Results

MaxMiamiFl Jun. 4 at 3:35 PM

$KYNB LETS GO!!!!!! $20++++++

1 · Reply

ARKADIY_PAROVOZOV Jun. 4 at 9:47 AM

$KYNB Roxadustat Impurity 175 added to PubChem database — technical update for research and quality control purposes. https://pubchem.ncbi.nlm.nih.gov/compound/Roxadustat-Impurity-175

0 · Reply

ARKADIY_PAROVOZOV Jun. 4 at 9:47 AM

0 · Reply

ARKADIY_PAROVOZOV Jun. 4 at 9:47 AM

0 · Reply

ARKADIY_PAROVOZOV Jun. 4 at 9:18 AM

$KYNB a strange premarket on stocktwits. Investing and yahoo are different from stocktwits.

0 · Reply

ARKADIY_PAROVOZOV Jun. 3 at 9:31 AM

1 · Reply

MaxMiamiFl Jun. 2 at 3:53 PM

$KYNB Any updates about the compliance topic??

1 · Reply

MaxMiamiFl Jun. 2 at 2:59 PM

$KYNB The imaging product can be a big winner. ....IF

0 · Reply

ARKADIY_PAROVOZOV Jun. 2 at 1:21 PM

0 · Reply

mjtwins16 Jun. 2 at 9:12 AM

$KYNB https://www.urotoday.com/conference-highlights/snmmi-2026/169541-snmmi-2026-first-in-human-cd46-targeted-immunopet-imaging-with-89zr-dfo-ys5-in-mcrpc.html

0 · Reply

ARKADIY_PAROVOZOV Jun. 2 at 7:29 AM

$KYNB Positive First-in-Human data for FG-3180 (CD46-targeted ImmunoPET) presented at SNMMI 2026. The imaging agent showed higher detection rates than conventional scans (144 bone lesions vs 99, 33 soft tissue sites vs 14) and good tumor uptake (SUVmax 11.7). Higher uptake also trended with better PSA50 response to FG-3246. https://www.urotoday.com/conference-highlights/snmmi-2026/169541-snmmi-2026-first-in-human-cd46-targeted-immunopet-imaging-with-89zr-dfo-ys5-in-mcrpc.html

0 · Reply

ARKADIY_PAROVOZOV Jun. 1 at 5:27 PM

$KYNB Kyntra Bio has refreshed their corporate website with a cleaner look and stronger emphasis on the FG-3246 oncology program. Looks like the company is preparing for the next stage. https://www.kyntrabio.com/

0 · Reply

ARKADIY_PAROVOZOV Jun. 1 at 1:58 PM

$KYNB New study on ResearchGate evaluates the switch from ESA to HIF-PHI (including Roxadustat) in non-dialysis-dependent CKD patients. Positive efficacy results observed after switching. https://www.researchgate.net/publication/405240101_Patient_characteristics_and_treatment_efficacy_after_switching_to_hypoxia-inducible_factor-prolyl_hydroxylase_inhibitors_from_erythropoiesis-stimulating_agents_in_non-dialysis-dependent_chronic_kidney

0 · Reply

ARKADIY_PAROVOZOV Jun. 1 at 1:56 PM

$KYNB New study in Kidney International Reports shows Roxadustat effectively improves anemia in patients undergoing peritoneal dialysis. Positive supporting data for the drug. https://www.kireports.org/article/S2468-0249(26)02121-2/pdf

0 · Reply

ARKADIY_PAROVOZOV Jun. 1 at 1:52 PM

$KYNB New systematic review & meta-analysis published in Pharmacological Research (May 2026) shows that HIF-PH inhibitors, including Roxadustat, significantly improve hemoglobin levels in CKD patients versus placebo. Good supporting data for the mechanism. https://www.sciencedirect.com/science/article/abs/pii/S1773224726005368

0 · Reply

ARKADIY_PAROVOZOV May. 29 at 1:06 PM

$KYNB Kyntra Bio Annual Shareholder Meeting is scheduled for June 12, 2026 at 8:00 AM PT (virtual format). https://www.virtualshareholdermeeting.com/KYNB2026

0 · Reply

ARKADIY_PAROVOZOV May. 29 at 11:32 AM

$KYNB New meta-analysis in BMC Nephrology (May 25, 2026) concludes that Roxadustat effectively increases hemoglobin and improves iron parameters in CKD patients undergoing peritoneal dialysis. Solid supporting data for the drug. https://www.deepdyve.com/lp/unpaywall/roxadustat-for-ckd-related-anemia-in-patients-undergoing-peritoneal-J0yfgXtj6P

0 · Reply

ARKADIY_PAROVOZOV May. 28 at 6:54 AM

$KYNB Dr. Andrew J. Armstrong, a leading prostate cancer expert at Duke Cancer Institute, is participating as an investigator in the FG-3246 Phase 2 trial (NCT06842498). Strong academic interest in the CD46-targeted ADC. https://www.dukecancerinstitute.org/dci-members/andrew-john-armstrong

0 · Reply

ARKADIY_PAROVOZOV May. 28 at 6:53 AM

$KYNB Recent paper in The FASEB Journal explores HIF-1α role in cellular metabolism, with references to Roxadustat. https://faseb.onlinelibrary.wiley.com/doi/10.1096/fj.202600149R

0 · Reply

ARKADIY_PAROVOZOV May. 28 at 6:51 AM

$KYNB A new publication on Roxadustat highlights its mechanism and potential application in the treatment of anemia. https://www.sciencedirect.com/science/article/abs/pii/S1773224726005368

0 · Reply

ARKADIY_PAROVOZOV May. 26 at 9:00 AM

$KYNB Phase 2 trial of FG-3246 (NCT06842498) in metastatic castration-resistant prostate cancer is actively recruiting. Interim analysis expected in Q4 2026. https://hipa.ai/study/NCT06842498

1 · Reply

ARKADIY_PAROVOZOV May. 25 at 6:47 AM

$KYNB New study published in Scientific Reports (Nature) explores the relationship between cytokines, microRNAs, and anemia in hemodialysis patients. Roxadustat is highlighted as a modern treatment option. https://www.nature.com/articles/s41598-026-53319-4

0 · Reply

Market Cap	27.57M
Revenue (ttm)	6.44M
Net Income (ttm)	183.45M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	2,848.60%
Debt to Equity Ratio	0.00

Volume	3,800
Avg Vol	11,572
Day's Range	N/A - N/A
Shares Out	4.05M
Stochastic %K	10%
Beta	1.01
Analysts	Sell
Price Target	$43.00